• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome.

作者信息

Hoeks Marlijn, Bagguley Tim, van Marrewijk Corine, Smith Alex, Bowen David, Culligan Dominic, Kolade Seye, Symeonidis Argiris, Garelius Hege, Spanoudakis Michail, Langemeijer Saskia, Roelofs Rian, Wiegerinck Erwin, Tatic Aurelia, Killick Sally, Panagiotidis Panagiotis, Stanca Oana, Hellström-Lindberg Eva, Cermak Jaroslav, van der Klauw Melanie, Wouters Hanneke, van Kraaij Marian, Blijlevens Nicole, Swinkels Dorine W, de Witte Theo

机构信息

Centre for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands.

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Leukemia. 2021 Jun;35(6):1745-1750. doi: 10.1038/s41375-020-01022-2. Epub 2020 Sep 18.

DOI:10.1038/s41375-020-01022-2
PMID:32948844
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8179850/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bcf/8179850/9473f0a077a3/41375_2020_1022_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bcf/8179850/9473f0a077a3/41375_2020_1022_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bcf/8179850/9473f0a077a3/41375_2020_1022_Fig1_HTML.jpg

相似文献

1
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome.低危骨髓增生异常综合征患者中的毒性铁物种：疾病进程及对预后的影响。
Leukemia. 2021 Jun;35(6):1745-1750. doi: 10.1038/s41375-020-01022-2. Epub 2020 Sep 18.
2
The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome.螯合疗法对输血性铁过载患者生存的影响：骨髓增生异常综合征的荟萃分析
Br J Haematol. 2014 Dec;167(5):720-3. doi: 10.1111/bjh.13053. Epub 2014 Jul 22.
3
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.不稳定的血浆铁水平可预测低危骨髓增生异常综合征患者的生存情况。
Haematologica. 2018 Jan;103(1):69-79. doi: 10.3324/haematol.2017.171884. Epub 2017 Nov 9.
4
Management of transfusion-related iron overload in patients with myelodysplastic syndromes.骨髓增生异常综合征患者输血相关铁过载的管理
Clin J Oncol Nurs. 2012 Jun;16 Suppl:37-46. doi: 10.1188/12.CJON.S1.37-46.
5
SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.伴有环形铁粒幼细胞的SF3B1突变型骨髓增生异常综合征存在更严重的铁过载及相应的红细胞生成过多。
Leuk Res. 2016 May;44:8-16. doi: 10.1016/j.leukres.2016.02.011. Epub 2016 Feb 27.
6
Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.骨髓增生异常综合征患者铁过载的临床后果：铁螯合疗法的情况
Expert Rev Hematol. 2018 Jul;11(7):577-586. doi: 10.1080/17474086.2018.1486188. Epub 2018 Jun 19.
7
Transfusional myocardial iron overload in myelodysplastic patients.骨髓增生异常患者的输血性心肌铁过载
Br J Haematol. 2008 Feb;140(3):361-2. doi: 10.1111/j.1365-2141.2007.06953.x. Epub 2007 Dec 7.
8
Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.输血依赖和继发性铁过载对骨髓增生异常综合征患者生存的影响。
Leuk Res. 2007 Dec;31 Suppl 3:S2-6. doi: 10.1016/S0145-2126(07)70459-9.
9
Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies.低危骨髓增生异常综合征患者接受铁螯合治疗与未接受螯合治疗的生存结局：观察性研究的综述与汇总分析
Leuk Res. 2017 Jun;57:104-108. doi: 10.1016/j.leukres.2017.03.007. Epub 2017 Mar 18.
10
Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?近期随机临床试验结果是否影响接受铁螯合治疗的骨髓增生异常综合征患者？
Hematol Oncol Clin North Am. 2020 Apr;34(2):465-473. doi: 10.1016/j.hoc.2019.10.006. Epub 2020 Jan 21.

引用本文的文献

1
Optimizing Timing and Preparation for Allogeneic Hematopoietic Stem Cell Transplantation in Higher-Risk Myelodysplastic Syndromes.优化高危骨髓增生异常综合征异基因造血干细胞移植的时机与准备工作。
Blood Lymphat Cancer. 2025 Aug 1;15:103-113. doi: 10.2147/BLCTT.S527790. eCollection 2025.
2
Advances and challenges in the treatment of myelodysplastic syndromes.骨髓增生异常综合征治疗的进展与挑战
Exp Hematol Oncol. 2025 Jun 18;14(1):87. doi: 10.1186/s40164-025-00678-9.
3
A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms.
骨髓增生异常综合征/肿瘤中无效红细胞生成与信号通路失调的相关性。
Exp Hematol Oncol. 2025 May 14;14(1):71. doi: 10.1186/s40164-025-00664-1.
4
Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromes.体细胞突变和DNA甲基化可识别低危骨髓增生异常综合征中预后不良的一个亚组。
Hemasphere. 2025 Jan 22;9(1):e70073. doi: 10.1002/hem3.70073. eCollection 2025 Jan.
5
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept.获得性铁粒幼细胞贫血和骨髓增生异常综合征中的铁过载：病理生理学以及螯合作用和罗特西普的作用
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):443-449. doi: 10.1182/hematology.2024000569.
6
[Research progress of iron metabolism and ferroptosis in myeloid neoplasms].[骨髓肿瘤中铁代谢与铁死亡的研究进展]
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024 Dec 25;53(6):735-746. doi: 10.3724/zdxbyxb-2024-0211.
7
MDS patient registries - achievements and challenges.骨髓增生异常综合征患者登记处——成就与挑战。
Ann Hematol. 2024 Dec;103(12):4913-4930. doi: 10.1007/s00277-024-05925-3. Epub 2024 Aug 23.
8
The Role of Hepcidin in Myelodysplastic Syndromes (MDS): A Systematic Review of Observational Studies.铁调素在骨髓增生异常综合征（MDS）中的作用：观察性研究的系统评价
Cancers (Basel). 2024 Jan 11;16(2):332. doi: 10.3390/cancers16020332.
9
Transfusion avoidance in myelodysplastic neoplasms.骨髓增生异常肿瘤中的输血回避。
Curr Opin Hematol. 2024 Mar 1;31(2):40-46. doi: 10.1097/MOH.0000000000000794. Epub 2023 Nov 16.
10
Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.环形铁幼粒细胞性难治性贫血伴 SF3B1 突变的红细胞分化增强 RNA 错剪接。
Cancer Res. 2024 Jan 16;84(2):211-225. doi: 10.1158/0008-5472.CAN-23-3038.